Quantum BioPharma

06/08/2026

Multiple sclerosis remains a major unmet medical challenge.

Quantum BioPharma's investigational drug candidate, Lucid-MS, is a new chemical entity (NCE) being developed to target citrullination-driven demyelination through a non-immunosuppressive and non-immunomodulatory approach.

Research suggests excessive citrullination may alter myelin proteins and contribute to myelin damage, impacting nerve signaling.

✅ Novel mechanism under investigation
✅ Focused on demyelination biology
✅ Addressing an important unmet need in MS research

Lucid-MS is investigational and not approved by the FDA or Health Canada.

$QNTM

www.quantumbiopharma.com

06/05/2026

Quantum BioPharma continues advancing its Lucid-MS program with a focus on demyelination and neuroprotective pathways in Multiple Sclerosis.

Phase 1 complete. IND submitted for Phase 2 trial design.

Lucid-MS is investigational and not approved by FDA or Health Canada.

Sign up for email alerts : https://quantumbiopharma.com/email-alerts


$QNTM

06/02/2026

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is featured in the latest episode of The BioMedWire Podcast, with Anthony Durkacz, Co-Founder and Executive Co-Chair, discussing the company’s Lucid-MS development program, unbuzzd™ commercial strategy, and key milestones ahead for 2026.

The conversation highlights Quantum BioPharma’s focus on multiple sclerosis research, demyelination, neurodegenerative disease, and the broader strategy behind its biotech and commercial asset portfolio.

Watch the full episode here:
https://www.youtube.com/watch?v=clA0PZNfY1A

Lucid-MS is an investigational drug candidate. It is not approved by the FDA, Health Canada, or any other regulatory authority. This post is for informational purposes only and does not constitute medical advice, investment advice, or a recommendation to buy or sell securities.

Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPh...

06/01/2026

Most approved MS therapies are designed to modulate or suppress the immune system.

But the immune system may not be the whole story.

For decades, MS treatment has largely focused on reducing immune-driven attacks. Quantum BioPharma
$QNTM
is exploring a different scientific question: whether MS also involves neurodegenerative mechanisms tied directly to myelin damage.

This is the demyelination pathway.

Lucid-MS, also known as LUCID-21-302, is being developed as a non-immunomodulatory investigational new chemical entity designed to target PAD2 an enzyme involved in abnormal myelin protein citrullination, a process believed to increase myelin vulnerability in MS.

In preclinical animal models, Lucid-MS demonstrated signals supporting further research into this mechanism.

Rather than targeting the immune system, Lucid-MS is focused on the biology of demyelination itself.

A different mechanism. A different pathway. A different approach to MS research. No Drugs currently on the market that are approved do what Lucid-MS is designed to do.

Lucid-MS is a Investigational drug candidate. Not approved by the FDA or Health Canada. Currently in clinical development.

05/26/2026

Quantum BioPharma recently announced a key midpoint milestone in its separate collaborative imaging study with Massachusetts General Hospital, centered on [¹⁸F]3F4AP PET imaging to help assess demyelination in Multiple Sclerosis.

While this study is separate from Lucid-MS trials, we believe this type of imaging research could one day help support the broader scientific understanding of how demyelination is measured and tracked in MS research.

Lucid-MS has completed prior Phase 1 clinical development, and Quantum BioPharma has submitted an IND application to the FDA for a Phase 2 clinical trial.

As Quantum BioPharma’s lead investigational candidate, Lucid-MS was designed to target neurodegenerative pathways linked to the citrullination cascade, representing a differentiated scientific approach from traditional immunomodulatory therapies.

Learn more in our May 18, 2026 news release.
https://www.globenewswire.com/news-release/2026/05/18/3296317/0/en/quantum-biopharma-reaches-key-midpoint-milestone-in-groundbreaking-imaging-study-with-massachusetts-general-hospital.html

$QNTM

05/26/2026

Quantum BioPharma is proud to support and help raise awareness for those living with Multiple Sclerosis.

“Living with MS can be unpredictable. One moment I have energy and the next I’m extremely fatigued. MS has taught me to listen to my body, set boundaries, and be aware of my stress levels. I always try to enjoy the present moment because you never know what tomorrow might bring.

I was living alone in a new city when I started experiencing symptoms. I didn’t have a family doctor at the time, so I was going to different walk-in clinics, and nobody could figure out what was going on. After multiple tests, hospital visits, and several MRIs, I was officially diagnosed with MS. It was heavy news to hear, especially without my family nearby.

I got involved with MS Walk because there are others in my community who experience similar challenges, but we don’t always share what we’re going through. Living with an invisible disability is a struggle. MS is part of my story and it’s important to me to spread awareness.

My family and friends have helped me talk openly about my diagnosis, without feeling like I have to hide it. It brings me peace of mind to know we’re raising awareness and funds for MS research to hopefully find a cure for this disease.

MS affects so many Canadians, and I want people to know they aren’t alone in their journey. My favourite part of MS Walk is being surrounded by others who understand what it’s like to live with MS—that sense of connection is everything.”

- Tina, diagnosed in 2019

Join MS Walk on May 31 and help make sure no one faces MS alone: bit.ly/4dKdtqN

05/26/2026

Stories like Diana Harrington’s remind us why MS awareness matters.

Behind every diagnosis is a person, a family, and often a caregiver offering daily love, patience, and support.

Quantum BioPharma is honoured to help raise awareness for the Multiple Sclerosis community. Thank you to the National MS Society for sharing Diana’s story and highlighting the strength of those living with MS and the families who stand beside them.

05/18/2026

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Promising Early Data Strengthens Potential of Novel PET Technology to Advance Development of Lucid-MS for Multiple Sclerosis

https://www.globenewswire.com/news-release/2026/05/18/3296317/0/en/quantum-biopharma-reaches-key-midpoint-milestone-in-groundbreaking-imaging-study-with-massachusetts-general-hospital.html

$QNTM

05/07/2026

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Investigational New Drug (IND) Application Filed to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

https://www.globenewswire.com/news-release/2026/05/07/3289803/0/en/quantum-reports-strengthened-liquidity-reduced-cash-burn-and-disciplined-cost-management-in-first-quarter-2026.html

$QNTM

05/06/2026

Supporting for all those affected by